Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ehud Zigmond

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Oncogene|September 21, 2018
Klotho suppresses colorectal cancer through modulation of the unfolded protein responseTammi Arbel Rubinstein, Shiri Shahmoon, Ehud Zigmond, et al.
Nature Medicine|October 27, 2020
Acute liver failure is regulated by MYC- and microbiome-dependent programsAleksandra A Kolodziejczyk, Sara Federici, Niv Zmora, et al.
Journal of Clinical Immunology|September 17, 2009
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cellsYaron Ilan, Ehud Zigmond, Gadi Lalazar, et al.
Antiviral Therapy|March 19, 2019
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life dataYael Gozlan, Efrat Bucris, Rachel Shirazi, et al.
The New England Journal of Medicine|February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisGideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
Antiviral Therapy|January 10, 2017
HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patientsYael Gozlan, Ziv Ben-Ari, Roy Moscona, et al.
Journal of Autoimmunity|September 25, 2019
The challenges of primary biliary cholangitis: What is new and what needs to be doneBenedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego Vergani, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Hepatology|July 1, 2022
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitisChristophe Corpechot, Fabrice Carrat, Farid Gaouar, et al.
Hepatology (Baltimore, Md.)|July 3, 2023
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Oncogene|September 21, 2018
Klotho suppresses colorectal cancer through modulation of the unfolded protein responseTammi Arbel Rubinstein, Shiri Shahmoon, Ehud Zigmond, et al.
Nature Medicine|October 27, 2020
Acute liver failure is regulated by MYC- and microbiome-dependent programsAleksandra A Kolodziejczyk, Sara Federici, Niv Zmora, et al.
Journal of Clinical Immunology|September 17, 2009
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cellsYaron Ilan, Ehud Zigmond, Gadi Lalazar, et al.
Antiviral Therapy|March 19, 2019
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life dataYael Gozlan, Efrat Bucris, Rachel Shirazi, et al.
The New England Journal of Medicine|February 21, 2024
A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisGideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, et al.
Antiviral Therapy|January 10, 2017
HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patientsYael Gozlan, Ziv Ben-Ari, Roy Moscona, et al.
Journal of Autoimmunity|September 25, 2019
The challenges of primary biliary cholangitis: What is new and what needs to be doneBenedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego Vergani, et al.
Hepatology (Baltimore, Md.)|June 30, 2023
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled studyGideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, et al.
Journal of Hepatology|July 1, 2022
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitisChristophe Corpechot, Fabrice Carrat, Farid Gaouar, et al.
Hepatology (Baltimore, Md.)|July 3, 2023
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, et al.
Pageof 6